Global Prostaglandin I2 Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Prostaglandin I2 Market Research Report 2024
Prostaglandin I2 (PGI), or prostacyclin, is one of the prostanoids, a group of local hormones that are best known for their roles in mediating inflammation.
According to Mr Accuracy reports’s new survey, global Prostaglandin I2 market is projected to reach US$ 3768.5 million in 2029, increasing from US$ 2457 million in 2022, with the CAGR of 6.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prostaglandin I2 market research.
The prostaglandin I2 (PGI2) market is driven by its critical role as a potent vasodilator and inhibitor of platelet aggregation, making it an essential therapeutic option for various cardiovascular conditions. PGI2, also known as prostacyclin, is used to treat pulmonary arterial hypertension (PAH), preventing blood clot formation and improving blood flow in affected patients. The increasing prevalence of PAH and the growing awareness of its therapeutic benefits contribute to market growth. Moreover, advancements in pharmaceutical research and biotechnology have led to the development of new formulations and delivery methods for PGI2, further expanding its application in cardiovascular medicine. However, the market also faces challenges, including the high cost of PGI2 therapy, which may limit patient access and affordability. Additionally, the need for continuous infusion in some cases and potential side effects, such as bleeding complications, can pose obstacles for widespread adoption. To succeed in this market, manufacturers must focus on cost-effectiveness, patient-friendly administration methods, and conducting extensive clinical trials to establish the safety and efficacy of PGI2 therapies for various cardiovascular conditions, ensuring its continued use as a critical treatment option.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prostaglandin I2 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
United Therapeutics
J & J
GSK
Teva
Toray
Tide Pharma
Bayer AG
Segment by Type
Epoprostenol Sodium
Treprostinil
Iloprost
Beraprost Sodium
For Injection
For Oral
For Inhalation
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prostaglandin I2 report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Prostaglandin I2 market is projected to reach US$ 3768.5 million in 2029, increasing from US$ 2457 million in 2022, with the CAGR of 6.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prostaglandin I2 market research.
The prostaglandin I2 (PGI2) market is driven by its critical role as a potent vasodilator and inhibitor of platelet aggregation, making it an essential therapeutic option for various cardiovascular conditions. PGI2, also known as prostacyclin, is used to treat pulmonary arterial hypertension (PAH), preventing blood clot formation and improving blood flow in affected patients. The increasing prevalence of PAH and the growing awareness of its therapeutic benefits contribute to market growth. Moreover, advancements in pharmaceutical research and biotechnology have led to the development of new formulations and delivery methods for PGI2, further expanding its application in cardiovascular medicine. However, the market also faces challenges, including the high cost of PGI2 therapy, which may limit patient access and affordability. Additionally, the need for continuous infusion in some cases and potential side effects, such as bleeding complications, can pose obstacles for widespread adoption. To succeed in this market, manufacturers must focus on cost-effectiveness, patient-friendly administration methods, and conducting extensive clinical trials to establish the safety and efficacy of PGI2 therapies for various cardiovascular conditions, ensuring its continued use as a critical treatment option.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prostaglandin I2 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
United Therapeutics
J & J
GSK
Teva
Toray
Tide Pharma
Bayer AG
Segment by Type
Epoprostenol Sodium
Treprostinil
Iloprost
Beraprost Sodium
Segment by Application
For Injection
For Oral
For Inhalation
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prostaglandin I2 report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices